Top Page
Covalon Technologies
(COV)
Covalon Technologies (COV) vs. S&P 500 (SPY)
Covalon Technologies Business Overview & Revenue Model
Covalon Technologies Financial Statement Overview
| Breakdown | |||||
| TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 34.67M | 31.17M | 26.60M | 18.15M | 19.56M | 25.80M | Gross Profit |
| 20.89M | 18.93M | 14.36M | 7.49M | 9.70M | 12.49M | EBIT |
| 2.96M | 0.00 | -4.49M | -9.14M | 838.34K | -6.09M | EBITDA |
| 5.98M | 3.14M | -3.49M | -8.11M | 1.54M | -6.63M | Net Income Common Stockholders |
| 4.73M | 2.67M | -4.46M | -9.66M | 23.48M | -6.95M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 17.50M | 16.75M | 8.79M | 14.06M | 22.95M | 3.51M | Total Assets |
| 34.82M | 31.81M | 24.90M | 30.38M | 40.58M | 34.70M | Total Debt |
| 784.67K | 901.67K | 1.56M | 2.17M | 2.59M | 20.90M | Net Debt |
| -16.71M | -15.85M | -7.23M | -11.89M | -20.36M | 17.40M | Total Liabilities |
| 4.17M | 4.30M | 6.11M | 6.15M | 7.21M | 25.59M | Stockholders Equity |
| 30.65M | 27.50M | 18.79M | 24.23M | 33.37M | 9.11M |
| Cash Flow | Free Cash Flow | ||||
| 2.99M | 3.06M | -4.50M | -9.08M | 443.71K | -4.40M | Operating Cash Flow |
| 3.50M | 3.47M | -3.18M | -7.99M | 621.37K | -4.03M | Investing Cash Flow |
| -384.12K | -281.63K | -81.02K | -843.02K | -278.53K | -370.41K | Financing Cash Flow |
| 5.01M | 4.97M | -2.16M | -2.19M | -8.25M | -1.75M |
Covalon Technologies Technical Analysis
Covalon Technologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | C$63.88M | 12.64 | 19.57% | ― | 38.28% | ― | |
63 Neutral | C$124.63M | ― | -24.49% | ― | -8.60% | 21.06% | |
58 Neutral | $21.35B | 10.05 | -19.26% | 2.35% | 5.02% | -22.63% | |
44 Neutral | C$12.38M | ― | -813.02% | ― | ― | ― | |
40 Underperform | C$100.24M | ― | ― | 6.07% | 80.33% |
Covalon Technologies Earnings Call Summary
Covalon Technologies Corporate Events
Covalon Technologies Ltd. reported a strong start to fiscal 2025 with its first quarter results showcasing significant revenue and earnings growth, driven primarily by its US Medical Consumables business. The company achieved a 75% year-over-year revenue increase, and notable earnings improvements, positioning it favorably in the market. Recent achievements include recognition as a top company on the TSX Ventures and OTCQX, securing a new patent, and expanding its hospital customer base, indicating strong future prospects.
Covalon Technologies Ltd. has been recognized as a 2025 Top 50 Company by the TSX Venture Exchange, highlighting its strong performance over the past year. This accolade reflects Covalon’s dedication to creating value through its product portfolios and its commitment to expanding and strengthening investor relationships in North America and beyond.
Covalon Technologies Ltd. has announced it will release its first quarter fiscal 2025 financial results on February 21, 2025, before the market opens. The company will hold a conference call and webcast on the same day at 8:30am ET to discuss the results, allowing participants to ask questions. This announcement could impact the company’s operations and provide insights into its financial health, influencing stakeholders and investors.
Covalon Technologies Ltd. has been recognized as a top-performing company, ranking fourth overall and first among medical device companies in the 2025 OTCQX Best 50 list. This accolade underscores Covalon’s robust market performance in 2024, marked by a total return of 207%, significantly surpassing the median returns of its peers. The recognition highlights growing international investor interest and positions Covalon as a promising player in the medical technology sector.
Covalon Technologies Ltd. has released a statement addressing the potential impacts of newly announced U.S. tariffs on Canadian imports. The company has operations in both Canada and the U.S. and plans to adapt its manufacturing processes to mitigate any negative financial implications. Covalon benefits from favorable foreign exchange rates, with revenues primarily in U.S. dollars and costs in Canadian dollars. The company recently concluded a successful fiscal year, achieving recognition as the top medical device company on the OTCQX’s Best 50 Companies list, and is committed to ensuring strong outcomes for its stakeholders amid the trade dispute.
Covalon Technologies Ltd. announced strong financial results for the fourth quarter and the fiscal year 2024, showcasing significant growth and profitability improvements. The company achieved a 29% increase in Q4 revenue and a 17% rise for the full year, alongside a notable turnaround in profitability with a substantial improvement in adjusted EBITDA and earnings per share. These results reflect Covalon’s commitment to enhancing its product offerings and delivering value to patients and clinicians, positioning itself for continued growth in 2025.
Covalon Technologies, an advanced medical technologies company, is set to release its fourth quarter and year-end fiscal 2024 financial results on January 7, 2025. The company will host a conference call and webcast on the same day to discuss these results, allowing participants to engage with management. Covalon offers innovative healthcare solutions focused on wound care, infection control, and medical device coatings.